Literature DB >> 19480930

Cytogenetic and real-time quantitative reverse-transcriptase polymerase chain reaction analyses in pleomorphic rhabdomyosarcoma.

Guidong Li1, Akira Ogose, Hiroyuki Kawashima, Hajime Umezu, Tetsuo Hotta, Tsuyoshi Tohyama, Takashi Ariizumi, Naoto Endo.   

Abstract

Pleomorphic rhabdomyosarcoma (PRMS) is a rare variant of rhabdomyosarcoma that occurs mostly in adults. A few cytogenetic studies of PRMS have been reported, but no consistent specific chromosome aberrations were detected. We herein report a cytogenetic study of three cases of pleomorphic rhabdomyosarcoma using a conventional G-banded karyotyping analysis. The three cases appeared to exhibit an extremely complex karyotype with numeric and structural rearrangements. Although the three cases displayed several common aberrations, including -2, -4, -9, -13, -14, -15, -19, -21, add(X)(p11), add(1)(q11), add(7)(p11), and add(13)(p11), no recurrent characteristic chromosomal aberrations could be detected. In addition, among these cases and seven other cases of previously reported PRMS, the most frequent chromosomal alterations were -2, -13, -14, -15, -16, and -19. No obviously consistent structural alterations can be found in these 10 PRMS cases, however, thereby suggesting that it is difficult to confirm whether these complex karyotypes correlated with the diagnosis or clinical outcome in PRMS. In this study, we detected MyoD1 and myogenin gene transcripts at the mRNA level in four cases of PRMS together with other soft-tissue sarcomas, including seven cases of malignant fibrous hitiocytoma, five cases of liposacroma, and three cases of leiomyosacroma using a real-time quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) analysis. High-level expressions of MyoD1 and myogenin gene transcripts were determined in all cases of PRMS. In contrast, the other non-PRMS sarcomas showed either no expression or extremely weak expressions for both genes. Our findings suggest that the detections of MyoD1 and myogenin transcripts using real-time quantitative RT-PCR, combined with immunohistochemical stains, are extremely sensitive and useful for the diagnosis of PRMS.

Entities:  

Mesh:

Year:  2009        PMID: 19480930     DOI: 10.1016/j.cancergencyto.2009.02.011

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  10 in total

Review 1.  Primary rhabdomyosarcoma of the distal femoral diaphysis: a case report and review of the literature.

Authors:  Jarred A Bressner; Edward F McCarthy; Laura M Fayad; Carol D Morris
Journal:  Skeletal Radiol       Date:  2016-07-13       Impact factor: 2.199

2.  Multiple sites of highly amplified DNA sequences detected by molecular cytogenetic analysis in HS-RMS-2, a new pleomorphic rhabdomyosarcoma cell line.

Authors:  Eiji Takaoka; Hiroshi Sonobe; Kunihiro Akimaru; Shuji Sakamoto; Taro Shuin; Masanori Daibata; Takahiro Taguchi; Akira Tominaga
Journal:  Am J Cancer Res       Date:  2012-02-19       Impact factor: 6.166

Review 3.  Soft tissue sarcomas with complex genomic profiles.

Authors:  Louis Guillou; Alain Aurias
Journal:  Virchows Arch       Date:  2010-02       Impact factor: 4.064

4.  Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus.

Authors:  Guidong Li; Hiroyuki Kawashima; Akira Ogose; Takashi Ariizumi; Yongjun Xu; Tetsuo Hotta; Yasuo Urata; Toshiyoshi Fujiwara; Naoto Endo
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-31       Impact factor: 4.553

5.  Fusion of the Paired Box 3 (PAX3) and Myocardin (MYOCD) Genes in Pediatric Rhabdomyosarcoma.

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Kristin Andersen; Marius Lund-Iversen; Svetlana Tafjord; Francesca Micci; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2021 Nov-Dec       Impact factor: 4.069

6.  Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma.

Authors:  Charles W Ashley; Arnaud Da Cruz Paula; Lorenzo Ferrando; Rodrigo Gularte-Mérida; Ana P M Sebastiao; David N Brown; Andrea M Gazzo; Fresia Pareja; Anthe Stylianou; Nadeem R Abu-Rustum; Jorge S Reis-Filho; Darya Buehler; Paul Weisman; Sarah Chiang; Britta Weigelt
Journal:  Histopathology       Date:  2021-04-19       Impact factor: 7.778

Review 7.  Evolving classification of rhabdomyosarcoma.

Authors:  Narasimhan P Agaram
Journal:  Histopathology       Date:  2022-01       Impact factor: 7.778

8.  Epithelioid Rhabdomyosarcoma; a case report with immunohistochemical and molecular study.

Authors:  Ryu Jokoji; Jun-ichiro Ikeda; Masahiko Tsujimoto; Eiichi Morii
Journal:  Diagn Pathol       Date:  2015-07-25       Impact factor: 2.644

9.  Status of programmed death-ligand 1 expression in sarcomas.

Authors:  Hyung Kyu Park; Mingi Kim; Minjung Sung; Seung Eun Lee; Yu Jin Kim; Yoon-La Choi
Journal:  J Transl Med       Date:  2018-11-06       Impact factor: 5.531

10.  The clinicopathologic spectrum and genomic landscape of de-/trans-differentiated melanoma.

Authors:  Ingrid Ferreira; Alastair Droop; Olivia Edwards; Kim Wong; Victoria Harle; Omar Habeeb; Deepa Gharpuray-Pandit; Joseph Houghton; Katharina Wiedemeyer; Thomas Mentzel; Steven D Billings; Jennifer S Ko; Laszlo Füzesi; Kathleen Mulholland; Ivana Kuzmic Prusac; Bernadette Liegl-Atzwanger; Nicolas de Saint Aubain; Helen Caldwell; Laura Riva; Louise van der Weyden; Mark J Arends; Thomas Brenn; David J Adams
Journal:  Mod Pathol       Date:  2021-06-21       Impact factor: 7.842

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.